Mercaptopurine
- Generic Name
- Mercaptopurine
- Brand Names
- Purixan, Xaluprine (previously Mercaptopurine Nova Laboratories)
- Drug Type
- Small Molecule
- Chemical Formula
- C5H4N4S
- CAS Number
- 50-44-2
- Unique Ingredient Identifier
- PKK6MUZ20G
- Background
An antimetabolite antineoplastic agent with immunosuppressant properties. It interferes with nucleic acid synthesis by inhibiting purine metabolism and is used, usually in combination with other drugs, in the treatment of or in remission maintenance programs for leukemia.
- Indication
For remission induction and maintenance therapy of acute lymphatic leukemia.
- Associated Conditions
- Acute Lymphoblastic Leukaemias (ALL), Acute Promyelocytic Leukemia, Autoimmune Hepatitis, Crohn's Disease (CD), Lymphoblastic Lymphoma, Ulcerative Colitis
- Associated Therapies
- -
Chemotherapy in Treating Patients With Acute Lymphoblastic Leukemia and Diffuse Non-Hodgkin's Lymphoma
- Locations
- 🇺🇸
Warren Grant Magnuson Clinical Center - NCI Clinical Studies Support, Bethesda, Maryland, United States
🇪🇬National Cancer Institute of Egypt, Cairo, Egypt
🇮🇳Kidwai Memorial Institute of Oncology, Bangalore, India
Alemtuzumab and Combination Chemotherapy in Treating Patients With Untreated Acute Lymphoblastic Leukemia
- Conditions
- Acute Undifferentiated LeukemiaB-cell Adult Acute Lymphoblastic LeukemiaB-cell Childhood Acute Lymphoblastic LeukemiaL1 Adult Acute Lymphoblastic LeukemiaL1 Childhood Acute Lymphoblastic LeukemiaL2 Adult Acute Lymphoblastic LeukemiaL2 Childhood Acute Lymphoblastic LeukemiaPhiladelphia Chromosome Negative Adult Precursor Acute Lymphoblastic LeukemiaPhiladelphia Chromosome Positive Adult Precursor Acute Lymphoblastic LeukemiaPhiladelphia Chromosome Positive Childhood Precursor Acute Lymphoblastic Leukemia
- Interventions
- Drug: allopurinolDrug: cyclophosphamideDrug: daunorubicin hydrochlorideDrug: vincristine sulfateDrug: dexamethasoneDrug: asparaginaseBiological: filgrastimDrug: imatinib mesylateDrug: methotrexateDrug: cytarabineDrug: trimethoprim-sulfamethoxazoleDrug: mercaptopurineDrug: leucovorin calciumBiological: alemtuzumabDrug: acyclovirOther: laboratory biomarker analysisOther: pharmacological study
- First Posted Date
- 2003-06-06
- Last Posted Date
- 2022-05-03
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 302
- Registration Number
- NCT00061945
- Locations
- 🇺🇸
Cancer and Leukemia Group B, Chicago, Illinois, United States
Comparison of Two Combination Chemotherapy Regimens With Either Vincristine or Vinblastine in Treating Patients With Advanced Anaplastic Large Cell Lymphoma
- Conditions
- Interventions
- First Posted Date
- 2003-05-07
- Last Posted Date
- 2014-09-22
- Lead Sponsor
- Children's Oncology Group
- Target Recruit Count
- 129
- Registration Number
- NCT00059839
- Locations
- 🇺🇸
All Children's Hospital, St. Petersburg, Florida, United States
🇺🇸Nemours Children's Clinic, Jacksonville, Florida, United States
🇵🇷San Jorge Children's Hospital, Santurce, Puerto Rico
Combination Chemotherapy With or Without Bone Marrow Transplantation in Treating Patients With Acute Promyelocytic Leukemia
- Conditions
- First Posted Date
- 2003-04-11
- Last Posted Date
- 2013-09-20
- Target Recruit Count
- 750
- Registration Number
- NCT00002701
- Locations
- 🇧🇪
Universitair Ziekenhuis Antwerpen, Edegem, Belgium
🇮🇹Federico II University Medical School, Naples (Napoli), Italy
🇮🇹Ospedale S. Gennora USL 42, Naples (Napoli), Italy
Combination Chemotherapy With or Without Donor Bone Marrow Transplantation in Treating Infants With Previously Untreated Acute Lymphoblastic Leukemia
- Conditions
- Interventions
- Drug: asparaginaseDrug: cyclophosphamideDrug: cyclosporineDrug: cytarabineDrug: daunorubicin hydrochlorideDrug: dexamethasoneDrug: doxorubicin hydrochlorideDrug: mercaptopurineDrug: methotrexateDrug: methylprednisoloneDrug: pegaspargaseDrug: thioguanineDrug: vincristine sulfateProcedure: allogeneic bone marrow transplantationRadiation: radiation therapy
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2014-02-20
- Lead Sponsor
- Children's Oncology Group
- Target Recruit Count
- 6
- Registration Number
- NCT00022126
- Locations
- 🇺🇸
Children's Hospital Los Angeles, Los Angeles, California, United States
🇺🇸Emory University Hospital - Atlanta, Atlanta, Georgia, United States
🇺🇸Loma Linda University Medical Center, Loma Linda, California, United States
Hormone Therapy Plus Chemotherapy in Treating Children With Acute Lymphoblastic Leukemia
- Conditions
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2013-12-04
- Lead Sponsor
- Medical Research Council
- Target Recruit Count
- 1800
- Registration Number
- NCT00003437
- Locations
- 🇬🇧
Oxford Radcliffe Hospital, Oxford, England, United Kingdom
Combination Chemotherapy in Treating Children With Acute Lymphoblastic Leukemia
- Conditions
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2014-02-20
- Lead Sponsor
- Children's Oncology Group
- Target Recruit Count
- 276
- Registration Number
- NCT00005603
- Locations
- 🇺🇸
Children's Hospital of Philadelphia, Philadelphia, Pennsylvania, United States
🇺🇸Children's Hospital Los Angeles, Los Angeles, California, United States
🇺🇸Dana-Farber Cancer Institute, Boston, Massachusetts, United States
Induction Intensification in Treating Infants With Newly Diagnosed Acute Lymphoblastic Leukemia
- Conditions
- Interventions
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2014-02-14
- Lead Sponsor
- Children's Oncology Group
- Target Recruit Count
- 221
- Registration Number
- NCT00002756
- Locations
- 🇺🇸
Children's Hospital Central California, Madera, California, United States
🇺🇸Winship Cancer Institute of Emory University, Atlanta, Georgia, United States
🇺🇸Kaplan Cancer Center at St. Mary's Medical Center, West Palm Beach, Florida, United States
Chemotherapy With or Without Bone Marrow Transplantation in Treating Patients With Acute Lymphoblastic Leukemia
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2013-06-12
- Target Recruit Count
- 392
- Registration Number
- NCT00002700
- Locations
- 🇸🇰
Institute of Hematology & Transfusiology, University Hospital, Bratislava, Slovakia
🇧🇪Hopital Universitaire Erasme, Brussels, Belgium
🇧🇪Universitair Ziekenhuis Antwerpen, Edegem, Belgium
Tretinoin, Cytarabine, and Daunorubicin Hydrochloride With or Without Arsenic Trioxide Followed by Tretinoin With or Without Mercaptopurine and Methotrexate in Treating Patients With Acute Promyelocytic Leukemia
- Conditions
- Interventions
- First Posted Date
- 2003-01-27
- Last Posted Date
- 2013-06-05
- Lead Sponsor
- National Cancer Institute (NCI)
- Target Recruit Count
- 420
- Registration Number
- NCT00003934
- Locations
- 🇺🇸
Cancer and Leukemia Group B, Chicago, Illinois, United States
🇺🇸Comprehensive Cancer Center of Wake Forest University, Winston-Salem, North Carolina, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.